1. Home
  2. SDA vs MDWD Comparison

SDA vs MDWD Comparison

Compare SDA & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SDA

SunCar Technology Group Inc.

HOLD

Current Price

$2.05

Market Cap

213.2M

Sector

Finance

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$17.05

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDA
MDWD
Founded
2007
2000
Country
China
Israel
Employees
N/A
N/A
Industry
Blank Checks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
213.2M
238.5M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
SDA
MDWD
Price
$2.05
$17.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$4.75
$37.50
AVG Volume (30 Days)
47.2K
91.0K
Earning Date
12-18-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$467,272,000.00
$20,932,000.00
Revenue This Year
$10.86
$15.89
Revenue Next Year
$13.07
$25.33
P/E Ratio
N/A
N/A
Revenue Growth
9.69
6.15
52 Week Low
$1.54
$14.14
52 Week High
$10.61
$22.51

Technical Indicators

Market Signals
Indicator
SDA
MDWD
Relative Strength Index (RSI) 53.08 38.61
Support Level $2.02 $16.32
Resistance Level $2.15 $19.70
Average True Range (ATR) 0.09 0.74
MACD 0.00 -0.23
Stochastic Oscillator 57.14 23.37

Price Performance

Historical Comparison
SDA
MDWD

About SDA SunCar Technology Group Inc.

SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: